Biotechnology - Licensing, Respiratory and Pulmonary

Filter

Popular Filters

Aslan Pharma signs agreement with CSL to develop novel therapy for asthma

19-05-2014

Singapore-based Aslan Pharmaceuticals has signed a global license agreement to develop an anti-interleukin…

ASLAN PharmaceuticalsBiotechnologyCSL LimitedCSL334LicensingRespiratory and Pulmonary

Cytos Biotech to wind down key operational activities

05-05-2014

Switzerland-based Cytos Biotechnology has entered into agreements with major creditors resulting in a…

BiotechnologyCYT003Cytos BiotechnologyFinancialLicensingRespiratory and Pulmonary

Whooping cough vaccine agreement signed by ILiAD

09-01-2014

US biotech company ILiAD Biotechnologies has signed scientific collaboration and worldwide license agreements…

BiotechnologyFranceILiAD BiotechnologiesLicensingResearchRespiratory and PulmonaryUSA

Stallergenes and DBV Technologies partner on developing novel respiratory allergies treatments

20-05-2013

French biotech firms DBV Technologies (Euronext: DBV), creator of Viaskin, a new standard in the treatment…

BiotechnologyDBV TechnologiesLicensingResearchRespiratory and PulmonaryStallergenes

Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs

13-05-2013

US biotech firm Theravance (Nasdaq: THRX) has entered into a royalty participation agreement wherein…

Anoro ElliptaBiotechnologyBreo ElliptaElanFinancialGlaxoSmithKlineLicensingPharmaceuticalRespiratory and PulmonaryTheravance

Infinity amends PI3K-delta, gamma accord with Millennium

28-12-2012

US drug discovery firm Infinity Pharmaceuticals (Nasdaq: INFI) says it has amended its development and…

BiotechnologyFinancialInfinity PharmaceuticalsIPI-145LicensingMillennium PharmaceuticalsPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

Ablynx extends Nanobody deal with Boehringer

21-03-2012

Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

US Rx cough/cold deal boosts Vernalis

14-02-2012

UK biotech firm Vernalis (LSE: VER) saw its share price rocket 28% to 25.2 pence last Friday, when the…

BiotechnologyLicensingNorth AmericaResearchRespiratory and PulmonaryTris PharmaVernalis

Company Spotlight

ImmunoGen

ImmunoGen

Back to top